Abstract: Described herein is a reversible aptamer selection technology for production-scale isolation of label-free cells (e.g., CD8+ T cells). Provided herein are methods for isolating a cell of interest from a biological sample by contacting the biological sample with an aptamer that specifically binds a cell surface marker specific for the cell of interest; separating the aptamer-bound cells from cells not bound to the aptamer; and recovering a cell of interest by disrupting binding of the aptamer to the cell surface marker.

Abstract: The invention is directed to a bispecific chimeric antigen receptor, comprising: (a) at least two antigen-specific targeting regions; (b) an extracellular spacer domain; (c) a transmembrane domain; (d) at least one co-stimulatory domain; and (e) an intracellular signaling domain, wherein each antigen-specific targeting region comprises an antigen-specific single chain Fv (scFv) fragment, and binds a different antigen, and wherein the bispecific chimeric antigen receptor is co-expressed with a therapeutic control. The invention also provides methods and uses of the bispecific chimeric antigen receptors.

Abstract: The coating can have a low-sweetness perception. During manufacturing and processing, the coating maintains a flowability to allow a glaze state of the coating to be applied to a food. Upon cooling, the glaze state of the coating forms a glass state that provides a low-sweetness impact which facilitates application of savory taste perceptions.

Abstract: A process is provided for producing a biomass material which is stabilised against oxidation. In particular, the process comprises the steps of: treating the concentrated biomass material with an antioxidant; and adjusting the pH of the concentrated biomass material to a pH of 7.0 or below. By means of these steps, a synergistic stabilisation of the biomass material is seen. An oxidation-stabilised biomass material is also provided, as well as an aquatic feed product, comprising the oxidation-stabilised biomass material.

Abstract: Apparatuses, systems, and methods relate to limiting torque applied to a rear axle. A vehicle includes a frame, a front tractive assembly coupled to the frame, a rear tractive assembly coupled to the frame, a prime mover coupled to the frame, a front tractive sensor, an output sensor, and a controller. The front tractive assembly includes a front axle. The rear tractive assembly includes a rear axle. The prime mover drives the front tractive assembly and the rear tractive assembly to propel the vehicle. The front tractive sensor collects data indicating a front power usage. The output sensor collects data indicating a power output of the prime mover. The controller is communicatively coupled to the front tractive sensor, the output sensor, and the prime mover. The controller de-rates the prime mover when the power output equals a sum of the power threshold and the front power usage.

Abstract: A continuous tire inflation system (CTIS) including a first outer O-ring, a second outer O-ring, a CTIS adopter in fluid communication to a trumpet housing, where the first outer O-ring and the second outer O-ring cause a seal between an outer surface of the CTIS adopter and the inner surface of the trumpet housing. The system including a first sealing bush adopter, a second sealing bush adopter, a first CTIS seal, a second CTIS seal, a first retaining ring configured to retain the first CTIS seal in physical contact with the CTIS adopter; a second retaining ring configured to retain the second CTIS seal in physical contact with the CTIS adopter.

Abstract: The invention is directed to a bispecific chimeric antigen receptor, comprising: (a) at least two antigen-specific targeting regions; (b) an extracellular spacer domain; (c) a transmembrane domain; (d) at least one co-stimulatory domain; and (e) an intracellular signaling domain, wherein each antigen-specific targeting region comprises an antigen-specific single chain Fv (scFv) fragment, and binds a different antigen, and wherein the bispecific chimeric antigen receptor is co-expressed with a therapeutic control. The invention also provides methods and uses of the bispecific chimeric antigen receptors.

Abstract: Apparatuses, systems, and methods relate to limiting torque applied to a rear axle. A vehicle includes a frame, a front tractive assembly coupled to the frame, a rear tractive assembly coupled to the frame, a prime mover coupled to the frame, a front tractive sensor, an output sensor, and a controller. The front tractive assembly includes a front axle. The rear tractive assembly includes a rear axle. The prime mover drives the front tractive assembly and the rear tractive assembly to propel the vehicle. The front tractive sensor collects data indicating a front power usage. The output sensor collects data indicating a power output of the prime mover. The controller is communicatively coupled to the front tractive sensor, the output sensor, and the prime mover. The controller de-rates the prime mover when the power output equals a sum of the power threshold and the front power usage.

Abstract: The coating can have a low-sweetness perception. During manufacturing and processing, the coating maintains a flowability to allow a glaze state of the coating to be applied to a food. Upon cooling, the glaze state of the coating forms a glass state that provides a low-sweetness impact which facilitates application of savory taste perceptions.

Abstract: The invention is directed to a bispecific chimeric antigen receptor, comprising: (a) at least two antigen-specific targeting regions; (b) an extracellular spacer domain; (c) a transmembrane domain; (d) at least one co-stimulatory domain; and (e) an intracellular signaling domain, wherein each antigen-specific targeting region comprises an antigen-specific single chain Fv (scFv) fragment, and binds a different antigen, and wherein the bispecific chimeric antigen receptor is co-expressed with a therapeutic control. The invention also provides methods and uses of the bispecific chimeric antigen receptors.

Abstract: An adjustable steering stop includes a chassis stop configured to be coupled to a chassis member of a vehicle and a knuckle stop configured to be coupled to a steering knuckle. The chassis stop and the knuckle stop together define a steering limit location where the knuckle stop contacts the chassis stop. The adjustable steering stop further includes an adjustment actuator coupled to one of the chassis stop or the knuckle stop to move the chassis stop or the knuckle stop thereby changing the steering limit location.

Abstract: Methods, systems, and devices for arranging, completing, and paying for healthcare services using a portal. The systems and methods include: (1) requesting a healthcare procedure, (2) scheduling the healthcare procedure, (3) confirming pricing for the healthcare procedure, (4) authorizing payment for the healthcare procedure, (5) funding the healthcare procedure, (6) completing the healthcare procedure, (7) paying for the healthcare procedure, and/or (8) communicating with the healthcare provider, the payor, and/or the facility using the portal.

Abstract: An axle assembly includes a connection assembly having a stationary portion and a rotary portion. The stationary portion is configured to couple to an inlet airflow assembly configured to be non-movably coupled to a beam housing, the rotary portion is configured to couple to an outlet airflow assembly configured to be non-movably coupled to a steering knuckle, the stationary portion forms a cavity configured to facilitate flow of pressurized air from the inlet airflow assembly to the rotary portion, and the rotary portion forms an airflow path configured to facilitate flow of the pressurized air from the cavity to the outlet airflow assembly.

Abstract: Hematopoietic stem/progenitor cells (HSPC) and/or non-T effector cells are genetically modified to express (i) an extracellular component including a ligand binding domain that binds a cellular marker preferentially expressed on an unwanted cell; and (ii) an intracellular component comprising an effector domain. Among other uses, the modified cells can be administered to patients to target unwanted cancer cells without the need for immunological matching before administration.

Abstract: Disclosed herein are methods and compositions for inactivation of the human glucocorticoid receptor (GR) gene by targeted cleavage of genomic DNA encoding the GR. Such methods and compositions are useful, for example, in therapeutic applications which require retention of immune function during glucocorticoid treatment.

Abstract: The coating can have a low-sweetness perception. During manufacturing and processing, the coating maintains a flowability to allow a glaze state of the coating to be applied to a food. Upon cooling, the glaze state of the coating forms a glass state that provides a low-sweetness impact which facilitates application of savory taste perceptions.

Abstract: Provided are methods of engulfing particles into droplets. The methods use a microfluidic device comprising a droplet generator and a chamber, the chamber comprising a liquid medium disposed on a voltage supply electrode and a ground electrode. The methods comprise dispensing a particle and a droplet into the liquid medium, and dielectrophoretically trapping the particle and the droplet using the voltage supply electrode and the ground electrode. The methods further comprise engulfing the particle into the droplet, wherein the engulfing comprises increasing a supply voltage between the voltage supply electrode and the ground electrode, thereby moving the droplet toward the voltage supply electrode and engulfing the particle into the droplet. In certain embodiments, the methods further comprise modifying the engulfed particle, assessing the engulfed particle, or both. Devices that find use in practicing the methods of the present disclosure are also provided.

Abstract: The invention is directed to a bispecific chimeric antigen receptor, comprising: (a) at least two antigen-specific targeting regions; (b) an extracellular spacer domain; (c) a transmembrane domain; (d) at least one co-stimulatory domain; and (e) an intracellular signaling domain, wherein each antigen-specific targeting region comprises an antigen-specific single chain Fv (scFv) fragment, and binds a different antigen, and wherein the bispecific chimeric antigen receptor is co-expressed with a therapeutic control. The invention also provides methods and uses of the bispecific chimeric antigen receptors.

Abstract: An adjustable steering stop includes a chassis stop configured to be coupled to a chassis member of a vehicle and a knuckle stop configured to be coupled to a steering knuckle. The chassis stop and the knuckle stop together define a steering limit location where the knuckle stop contacts the chassis stop. The adjustable steering stop further includes an adjustment actuator coupled to one of the chassis stop or the knuckle stop to move the chassis stop or the knuckle stop thereby changing the steering limit location.

Abstract: The coating can have a low-sweetness perception. During manufacturing and processing, the coating maintains a flowability to allow a glaze state of the coating to be applied to a food. Upon cooling, the glaze state of the coating forms a glass state that provides a low-sweetness impact which facilitates application of savory taste perceptions.